<- Go Home
Silverback Therapeutics, Inc.
As of November 8, 2022, Silverback Therapeutics, Inc. was acquired by ARS Pharmaceuticals, Inc., in a reverse merger transaction. Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Market Cap
$210.6M
Volume
381.4K
Cash and Equivalents
$203.2M
EBITDA
-$78.4M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$10.8M
Profit Margin
N/A
52 Week High
$8.97
52 Week Low
$2.80
Dividend
N/A
Price / Book Value
0.79
Price / Earnings
-2.41
Price / Tangible Book Value
0.79
Enterprise Value
-$55.8M
Enterprise Value / EBITDA
0.73
Operating Income
-$79.1M
Return on Equity
28.50%
Return on Assets
-15.86
Cash and Short Term Investments
$266.6M
Debt
$215.0K
Equity
$267.1M
Revenue
N/A
Unlevered FCF
-$39.6M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium